Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Decitabine +/- Venetoclax in Relapsed/Refractory AML or MDS
NCT03969446Phase 1Suspended
- Sponsor
- City of Hope
- Start
- May 2020
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 cohorts), sponsored by City of Hope. Primary endpoints: Incidence of adverse events at 2 years, Maximum-tolerated dose at 42 days and 1 more. Started May 2020; status: suspended.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03969446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969446.